Congress is back in session. With the election looming, this means a frenetic dash to pass bills on a number of big ticket items, including the budget and Zika funding. While the legislative fight over these issues will likely dominate the headlines, we cannot forget about other below-the-radar, but nevertheless critical, issues. One critical, but below-the radar, issue is a Senate bill that could force the manufacturer of innovative drugs that are used to treat serious illnesses to prematurely turn over samples and patented information to generic manufacturers.
Read Full Article »
